NASDAQ:IRD Opus Genetics (IRD) Stock Price, News & Analysis $4.58 +0.07 (+1.55%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$4.64 +0.05 (+1.20%) As of 10/2/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Opus Genetics Stock (NASDAQ:IRD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Opus Genetics alerts:Sign Up Key Stats Today's Range$4.45▼$4.6750-Day Range$3.35▼$6.0752-Week Range$1.70▼$7.07Volume1.79 million shsAverage Volume5.01 million shsMarket Capitalization$378.54 millionP/E RatioN/ADividend YieldN/APrice Target$11.92Consensus RatingModerate Buy Company Overview Opus Genetics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases, a group of rare disorders that can cause progressive vision loss and blindness. The company’s research is centered on therapies intended to address the underlying genetic causes of these conditions rather than treating only their symptoms. Opus Genetics is advancing an investigational pipeline of adeno-associated virus-based gene therapy candidates for diseases involving mutations in genes important to retinal function. Its programs are designed to deliver functional genetic material or otherwise correct disease-related biological processes in retinal cells. The company’s lead programs target selected forms of inherited retinitis pigmentosa and other rare retinal disorders. Founded in 2017, Opus Genetics is based in Durham, North Carolina, and conducts its development activities through collaborations with researchers, medical institutions, and clinical trial sites. As its therapies remain investigational, their safety and effectiveness have not been established for general use.AI Generated. May Contain Errors. Read More Opus Genetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreIRD MarketRank™: Opus Genetics scored higher than 71% of companies evaluated by MarketBeat, and ranked 183rd out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingOpus Genetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 15 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialOpus Genetics has a consensus price target of $11.92, representing about 160.3% upside from its current price of $4.58.Amount of Analyst CoverageOpus Genetics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Opus Genetics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Opus Genetics are expected to grow in the coming year, from ($0.99) to ($0.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Opus Genetics is -3.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Opus Genetics is -3.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOpus Genetics has a P/B Ratio of 20.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Opus Genetics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.24% of the float of Opus Genetics has been sold short.Short Interest Ratio / Days to CoverOpus Genetics has a short interest ratio ("days to cover") of 1.51, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Opus Genetics has recently increased by 15.27%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOpus Genetics does not currently pay a dividend.Dividend GrowthOpus Genetics does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.27 News SentimentOpus Genetics has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Opus Genetics this week, compared to 6 articles on an average week.Search Interest12 people have searched for IRD on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows4 people have added Opus Genetics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Opus Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,971,509.00 in company stock.Percentage Held by Insiders11.70% of the stock of Opus Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions14.97% of the stock of Opus Genetics is held by institutions.Read more about Opus Genetics' insider trading history. Receive IRD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opus Genetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IRD Stock News HeadlinesOpus Genetics (NASDAQ:IRD) Stock Rating Reaffirmed as "Buy" by Chardan CapitalOctober 4 at 2:32 AM | americanbankingnews.comWall Street Zen Upgrades Opus Genetics (NASDAQ:IRD) to "Hold"October 4 at 1:07 AM | americanbankingnews.comWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has noticed it. Altucher believes the filing could matter to as many as 1,806,000 Americans in the years ahead. He explains why Musk buried it and what it could mean, free of charge.October 4 at 1:00 AM | Paradigm Press (Ad)Opus Genetics (NASDAQ:IRD) Stock: Insider Fighting Blindness Foundation Sells 556,000 SharesOctober 3 at 5:22 AM | insidertrades.comOpus Genetics, Inc. (NASDAQ:IRD) Stock Has Consensus Price Target of $11.92October 1 at 4:15 AM | americanbankingnews.comHead-To-Head Review: ProQR Therapeutics (NASDAQ:PRQR) versus Opus Genetics (NASDAQ:IRD)September 26, 2026 | americanbankingnews.comWall Street Zen Downgrades Opus Genetics (NASDAQ:IRD) to SellSeptember 26, 2026 | americanbankingnews.comOpus Genetics (NASDAQ:IRD) CFO Sells $127,120.00 in StockSeptember 9, 2026 | insidertrades.comSee More Headlines IRD Stock Analysis - Frequently Asked Questions How have IRD shares performed this year? Opus Genetics' stock was trading at $2.01 at the beginning of the year. Since then, IRD stock has increased by 127.9% and is now trading at $4.58. How were Opus Genetics' earnings last quarter? Opus Genetics, Inc. (NASDAQ:IRD) released its earnings results on Thursday, August, 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.02. The company had revenue of $0.76 million for the quarter, compared to the consensus estimate of $2.63 million. How do I buy shares of Opus Genetics? Shares of IRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/06/2026Today10/04/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 IRD's financial health is in the Green zone, according to TradeSmith. IRD has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IRD Previous SymbolNASDAQ:IRD CIK1228627 Webwww.opusgtx.com Phone248-957-9024Fax240-268-5310Employees28Year Founded2018Price Target and Rating Average Price Target for Opus Genetics$11.92 High Price Target$20.00 Low Price Target$7.00 Potential Upside/Downside+160.3%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)($1.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$49.59 million Net Margins-1,091.82% Pretax Margin-1,091.82% Return on EquityN/A Return on Assets-150.13% Debt Debt-to-Equity RatioN/A Current Ratio12.19 Quick Ratio12.19 Sales & Book Value Annual Sales$14.20 million Price / Sales26.66 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book20.82Miscellaneous Outstanding Shares82,650,000Free Float72,978,000Market Cap$378.54 million OptionableN/A Beta0.62 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:IRD) was last updated on 10/4/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...Paradigm Press | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
